Form 4: Guardant Health Co-CEO AmirAli Talasaz Reports Significant Stock Transactions Under Pre-Arranged 10b5-1 Plan

Guardant Health's Co-Chief Executive Officer, AmirAli Talasaz, reported the acquisition of common stock through RSU vesting and subsequent sales and tax withholdings, primarily executed under a pre-arranged 10b5-1 trading plan.

Summary

• AmirAli Talasaz, Co-CEO and Director of Guardant Health, Inc. (GH), reported multiple transactions involving the company's common stock on June 30, 2025, and July 1, 2025.
• On June 30, 2025, Talasaz acquired 4,815 shares of common stock through the exercise of restricted stock units (RSUs) at a price of $0. Following this acquisition, direct beneficial ownership was 2,074,271 shares.
• Concurrently on June 30, 2025, 2,441 shares were disposed of at $52.04 to cover tax withholding obligations related to the RSU vesting, reducing beneficial ownership to 2,071,830 shares.
• On July 1, 2025, two separate sales of common stock occurred under a Rule 10b5-1 trading plan adopted on December 17, 2024: 72,068 shares were sold at a weighted average price of $50.6715, and 27,932 shares were sold at a weighted average price of $51.4047. These sales collectively reduced beneficial ownership to 1,971,830 shares.
• Also on July 1, 2025, Talasaz acquired an additional 23,997 shares of common stock through the exercise of restricted stock units (RSUs) at a price of $0, increasing beneficial ownership to 1,995,827 shares.
• Finally, on July 1, 2025, 12,162 shares were disposed of at $50.71 to cover tax withholding obligations related to RSU vesting, resulting in a final direct beneficial ownership of 1,983,665 shares.
• Overall, the reported transactions resulted in a net decrease of 90,606 shares in AmirAli Talasaz's direct beneficial ownership of Guardant Health common stock from the initial reported amount after the first transaction to the final reported amount.

Sentiment

Score: 5

Explanation: The document is a routine insider trading report. It contains no positive or negative news about the company's operations or financial performance. The sales are under a 10b5-1 plan, which mitigates negative interpretations of insider selling, placing the sentiment at neutral.

Positives

• The sales of common stock were conducted under a Rule 10b5-1 trading plan, indicating pre-planned transactions rather than reactive selling, which can mitigate negative market interpretations.
• The acquisition of shares through RSU vesting demonstrates continued equity compensation for the Co-CEO, aligning executive incentives with shareholder interests.

Negatives

• A significant disposition of common stock by a Co-CEO occurred, totaling 100,000 shares through sales and an additional 14,603 shares for tax withholding, resulting in a net decrease of 90,606 shares in direct beneficial ownership.
• The sales occurred at prices ranging from $50.08 to $51.94, which, if not for the pre-arranged 10b5-1 plan, might be perceived as a lack of confidence.

Risks

• Insider selling, even when conducted under a pre-planned Rule 10b5-1 trading plan, can sometimes be misinterpreted by the market as a lack of confidence in the company's future prospects, potentially leading to negative sentiment or short-term stock price volatility.

Future Outlook

The document does not contain forward-looking statements or guidance regarding the company's future performance, strategic direction, or financial estimates. It solely reports insider trading activities.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, common across all publicly traded companies. It reflects an executive's pre-planned stock transactions, which are typical for managing equity compensation and personal financial planning. It does not provide specific insights into broader industry trends or the competitive landscape within the biotechnology or healthcare sectors.

Comparison to Industry Standards

• This document reports standard insider transactions (RSU vesting, tax withholding, and sales under a 10b5-1 plan). Such transactions are common across executives in publicly traded companies, particularly in high-growth sectors like biotechnology, where equity compensation is a significant component of remuneration.
• The use of a Rule 10b5-1 plan aligns with best practices for corporate insiders to manage their stock holdings while avoiding accusations of trading on material non-public information, a standard adopted by many executives across various industries.
• There are no specific comparable companies, projects, or results mentioned in the document to benchmark Guardant Health's operational or financial performance against industry peers.

Stakeholder Impact

• Shareholders: The sale of shares by a Co-CEO, even under a 10b5-1 plan, could be viewed with caution by some investors, though the pre-planned nature typically reduces negative sentiment. The reduction in direct beneficial ownership by 90,606 shares represents a minor change relative to the company's total outstanding shares but a notable reduction in the insider's direct stake.

Next Steps

• Continued quarterly vesting of a restricted stock unit award for the remaining twenty-four months.
• Remaining vesting installments for another RSU award on September 30, 2025, and December 31, 2025.

Key Dates

Recommendation

Keywords

Guardant Health, GH, SEC Form 4, Insider Trading, AmirAli Talasaz, Stock Sale, RSU Vesting, 10b5-1 Plan, Executive Compensation, Biotechnology, Healthcare, Oncology